Cargando…

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer

The use of genomics to discover novel targets and biomarkers has placed the field of oncology at the forefront of precision medicine. First-generation epidermal growth factor receptor (EGFR) inhibitors have transformed the therapeutic landscape of EGFR mutant non-small-cell lung carcinoma through th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yap, Timothy A, Popat, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178554/ https://www.ncbi.nlm.nih.gov/pubmed/25278773 http://dx.doi.org/10.2147/PGPM.S55339

Ejemplares similares

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
por: Li, Yufeng, et al.
Publicado: (2023)

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
por: Richer, Amanda L, et al.
Publicado: (2015)

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
por: Sundar, Raghav, et al.
Publicado: (2017)

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
por: Sattler, Martin, et al.
Publicado: (2023)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
por: Wang, Xiaochun, et al.
Publicado: (2016)

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
por: Jin, Ying, et al.
Publicado: (2016)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Clinical Next Generation Sequencing for Precision Medicine in Cancer
por: Dong, Ling, et al.
Publicado: (2015)

Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review
por: Yu, Li, et al.
Publicado: (2017)

Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer
por: Niu, Lin, et al.
Publicado: (2021)

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
por: Eno, Meredith S., et al.
Publicado: (2022)

Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
por: Hou, Helei, et al.
Publicado: (2017)

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
por: Garon, E.B., et al.
Publicado: (2023)

Next generation informatics for big data in precision medicine era
por: Zhang, Yuji, et al.
Publicado: (2015)

Targeted next generation sequencing as a tool for precision medicine
por: Gulilat, Markus, et al.
Publicado: (2019)

Next-generation sequencing improves precision medicine in hearing loss
por: Imizcoz, T., et al.
Publicado: (2023)

Towards precision oncology in angiosarcomas using next generation “omic” technologies
por: Tan, Grace Fangmin, et al.
Publicado: (2021)

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Qi, Yi-Tian, et al.
Publicado: (2020)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Building towards precision medicine: empowering medical professionals for the next revolution
por: McGrath, Scott, et al.
Publicado: (2016)

Changing paradigm of cancer therapy: precision medicine by next-generation sequencing
por: Xue, Yuan, et al.
Publicado: (2016)

Lifestyle precision medicine: the next generation in type 2 diabetes prevention?
por: Mutie, Pascal M., et al.
Publicado: (2017)

Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines
por: Ramamoorthy, Anuradha, et al.
Publicado: (2019)

Bioinspired skin towards next-generation rehabilitation medicine
por: Wang, Zhenghui, et al.
Publicado: (2023)

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
por: Kuang, Shelley, et al.
Publicado: (2022)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
por: Bai, Yongkang, et al.
Publicado: (2023)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer
por: Park, Hwangseo, et al.
Publicado: (2020)

Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer
por: Li, Mu-Chun, et al.
Publicado: (2023)

The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology
por: Morash, Margaret, et al.
Publicado: (2018)

Comparative analyses of error handling strategies for next-generation sequencing in precision medicine
por: F. Löchel, Hannah, et al.
Publicado: (2020)

Application of next generation sequencing in cardiology: current and future precision medicine implications
por: Papadopoulou, Eirini, et al.
Publicado: (2023)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
por: Berardi, Rossana, et al.
Publicado: (2013)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing
por: Pujol, Nina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pmje77uolmis514jjphj24i2j5